In breast cancer, ELOVL2 acts as a tumor suppressor by attenuating tamoxifen resistance (Jeong et al., 2021), whereas in renal cell carcinoma, it promotes tumor progression by inhibiting apoptosis. Here, ELOVL2 is linked to breast carcinoma.